Adverum Biotechnologies (LSE:0HA3) - Hisse Senedi Fiyatı, Haberler ve Analizler

0HA3 Stoklara Genel Bakış

Klinik aşamada bir şirket olan Adverum Biotechnologies, Inc. oküler hastalıkları tedavi etmek için gen terapisi ürün adayları geliştirmektedir. Daha fazla detay

0HA3 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 47.34% oranında artması öngörülüyor

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 16.9% oranında düşmesi öngörülüyor

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $1,000K )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 1 daha fazla risk

Adverum Biotechnologies, Inc. Rakipler

PureTech Health

LSE:PRTC

UK£415.6m

Faron Pharmaceuticals Oy

AIM:FARN

UK£159.6m

Bioventix

AIM:BVXP

UK£204.9m

e-therapeutics

AIM:ETX

UK£52.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Adverum Biotechnologies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.41
52 Haftanın En Yüksek Seviyesi	US$29.50
52 Haftanın En Düşük Seviyesi	US$6.43
Beta	1.01
11 Aylık Değişim	-4.88%
3 Aylık Değişim	12.96%
1 Yıllık Değişim	-14.77%
33 Yıllık Değişim	-63.64%
5 Yıllık Değişim	-86.55%
Halka arzdan bu yana değişim	-89.41%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0HA3	GB Biotechs	GB Pazar
7D	-5.9%	-1.7%	-1.0%
1Y	-14.8%	-19.2%	6.9%

Getiri vs. Endüstri: 0HA3 geçen yıl % -19.2 oranında getiri sağlayan UK Biotechs sektörünü aştı.

Getiri vs Piyasa: 0HA3 geçen yıl % 6.9 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 0HA3's price volatile compared to industry and market?
0HA3 volatility
0HA3 Average Weekly Movement	7.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.1%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0HA3 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 0HA3 'nin haftalık oynaklığı son bir yılda 13% dan 8% a düştü, ancak hâlâ UK hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2006	121	Laurent Fischer	adverum.com

Klinik aşamada bir şirket olan Adverum Biotechnologies, Inc. oküler hastalıkları tedavi etmek için gen terapisi ürün adayları geliştirmektedir. Şirketin öncü ürün adayı, yaşlılığa bağlı makula dejenerasyonu ve diyabetik makula ödemi olan hastaların tedavisinde kullanılan ve faz 2 klinik çalışmalarında olan tek intravitreal enjeksiyon gen terapisi adayı ixoberogene soroparvovec'tir (ADVM-022). Şirket, tek bir IVT enjeksiyonu yoluyla mavi koni monokromisinin tedavisi için yeni bir gen terapisi ürün adayı olan ADVM-062'yi (AAV.7m8-L-opsin) geliştirmektedir.

Adverum Biotechnologies, Inc. Temel Bilgiler Özeti

Adverum Biotechnologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0HA3 temel i̇stati̇sti̇kler
Piyasa değeri	US$157.27m
Kazançlar(TTM)	-US$94.11m
Gelir(TTM)	US$1.00m

150.8x

P/S Oranı

-1.6x

F/K Oranı

0HA3 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0HA3 gelir tablosu (TTM)
Gelir	US$1.00m
Gelir Maliyeti	US$68.22m
Brüt Kâr	-US$67.22m
Diğer Giderler	US$26.89m
Kazançlar	-US$94.11m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.52
Brüt Marj	-6,722.40%
Net Kâr Marjı	-9,411.10%
Borç/Özkaynak Oranı	0%

0HA3 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

0HA3 Stoklara Genel Bakış

Ödüller

Risk Analizi

Adverum Biotechnologies, Inc. Rakipler

LSE:PRTC

UK£415.6m

AIM:FARN

UK£159.6m

AIM:BVXP

UK£204.9m

AIM:ETX

UK£52.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold US$109k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought US$99k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought US$115k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Adverum Biotechnologies, Inc. Temel Bilgiler Özeti

150.8x

-1.6x

Kazanç ve Gelir